AAIT™ Widens Options for Lung Cancer Patients

Adoptive Autologous Immunotherapy (AAIT™) introduces a revolutionary class of cancer treatment that is specifically designed to enhance response rates in lung cancer patients. By isolating tumor-infiltrating lymphocytes (TILs) from your blood sample and expanding them in a laboratory environment, AAIT™ significantly amplifies the body’s inherent capability to fight cancer.

In clinical trials, adoptive cell transfer methods, like AAIT™, have demonstrated promising improvements to patient outcomes in cases of advanced and resistant forms of lung cancer, including aggressive types such as non-small cell lung cancer (NSCLC) [1,2]. AAIT™ is also a powerful adjuvant to conventional treatment in early-stage cancer. It’s versatility and compatibility with other forms of treatment make AAIT™ a viable option for a comprehensive cancer care plan.

This personalized, cell-based approach to cancer care harnesses the power of the immune system itself to combat cancer cells at both the tumor site and throughout the body [3]. AAIT™ holds the potential of dramatically transforming outcomes for patients dealing with early as well as late-stage lung cancers.

AAIT™ represents a leading, experimental edge in lung cancer treatment, which has started entering mainstream cancer therapy through rigorous clinical trials over the past decade and more [4]. For patients with early-stage disease and with late-stage and aggressive lung cancer, AAIT™ extends hope for an active and durable response [5,6]. AAIT™ is a form of personalized medicine on two levels.

The treatment involves utilizing your body’s own cells, which are drawn from the blood and expanded in a laboratory setting before being returned to your body. The treatment is personalized again by using fresh biopsies from your specific cancer to train the two types of specialized cell of your innate immune system, the natural killer (NK) and dendritic cells. These cells are expanded in the laboratory, empowering them to launch a stronger attack against the disease. The result of this process leaves patients with stronger immune cells, which are native to their body (not taken from a donor) and have shown the ability to identify and attack your specific strain of cancer.

This level of precision in medical care offers a promising improvement to outcomes for those dealing with advanced stages of lung cancer and can halt the development of disease in its tracts for those with earlier disease staging [7,8]. AAIT™ may be the beginning of a transformative shift in the management of lung cancer, aiming for sustained remission and improved quality of life, across all stages of disease.

The integration of adoptive cell transfer therapies, like AAIT™, into the broader landscape of cancer treatment has shown significant promise, especially for lung cancer patients. This class of therapy represents a powerful addition to the arsenal against cancer and marks a departure from the harsh side effects of chemotherapy by leveraging your own immune system to target and destroy cancer cells. The versatility of AAIT™ affords it a wide compatibility with other forms of cancer intervention. The combination of multiple therapies at once often has a synergistic effect that enhances overall treatment effectiveness.

AAIT™ can be combined with conventional cancer therapy such as chemotherapy and radiation [9] and doesn’t interfere with emerging therapies like checkpoint inhibitors or other forms of immunotherapy either [10]. By combining two or more therapies concurrently, a more hostile environment for cancer cells is created in the body, preventing their growth and spread. For example, chemotherapy and radiation can reduce tumor burden and potentially expose new antigens, making cancer cells more susceptible to recognition and destruction by both innate T cells and those introduced by AAIT™ [11].

Further, targeting the tumor microenvironment with secondary therapies can modulate immune suppression, improving the effectiveness of AAIT™ [12]. A multifaceted approach enhances the direct cytotoxic effect on tumor cells and seeks to overcome the immune evasion strategies employed by tumor cells, thereby addressing one of the major challenges in cancer treatment.

These developments underscore the potential of adoptive cell transfer to work in concert with a wide range of cancer therapies. AAIT™ goes beyond the scope of standard treatment options, to optimize outcomes for lung cancer patients, as well as those with other forms of cancer. The team of specially trained clinicians at Envita are paving the way for more effective and personalized cancer treatments by harnessing and enhancing the patient’s own immune system.

Adoptive cell therapies, like AAIT™, have shown significant promise in the treatment of various cancers, including lung cancer. As of the time of this writing, the interest in CAR T-cell therapy for lung cancer is especially great [13]. The principle behind AAIT™ involves the collection and modification of your immune cells, which are then infused back into your body to fight the cancer more effectively.

In recent years, this innovative approach has been explored for its potential application in solid tumors, including lung cancer [14-16]. A meta-analysis of adoptive immunotherapy (AAIT™) in post-operative lung cancer patients revealed its potential to improve patient survival [17]. The study adds to the wealth of research that corroborates the place for AAIT™ alongside conventional treatments, like chemotherapy and surgical excision of solid tumors.

This body of research exemplifies the cutting-edge advancements in adoptive cell therapy (AAIT™) and its potential to radicalize cancer treatment. By drawing on the latest results of clinical trials, such as investigations into CAR T-cell therapy, we gain insights into the effectiveness of AAIT™ across a range of cancers, including lung cancer. The ongoing development and refinement of adoptive cell therapies, like AAIT™, hold promise for more targeted, effective, and personalized cancer treatments in the future.